Navigation Links
Scripps Health/the Medicines Company announce late breaking BRIDGE trial results presented at TCT
Date:11/9/2011

ior to cardiac surgery. Results also show control of platelet function as there was a rapid offset of platelet inhibition after stopping the cangrelor infusion prior to surgery."

According to 2009 data from the Organisation for Economic Co-operation and Development (OECD), more than 2.5 million PCIs are performed globally per year. Treatment guidelines in the United States and Europe recommend stent patients receive oral P2Y12 inhibitors for up to 12 months following percutaneous coronary intervention (PCI). It is estimated that up to 25 percent of these patients with stents in place will require a surgical procedure during the first five years after PCI.

Dimitrios Goundis, PhD, head of R&D at The Medicines Company added, "With strong patient enrollment in the Phase 3 PHOENIX trial of cangrelor in PCI patients and these results from the BRIDGE trial, there is great momentum with the cangrelor program, which is an important part of our portfolio of acute and intensive care hospital compounds."

Summary methods and results

The first stage of BRIDGE identified the cangrelor dose that maintains a 'thienopyridine-like' level of platelet inhibition. The second stage reported today was a prospective, randomized, double-blind, placebo-controlled trial in 210 patients with an acute coronary syndromes (ACS) or treated with a coronary stent (bare metal stent or drug eluting stent) on a thienopyridine awaiting coronary artery bypass grafting (CABG). After thienopyridine discontinuation (<72 hours), patients were administered cangrelor or placebo for at least 48 hours and up to 7 days, which was discontinued 1-6 hours prior to CABG. The objective was to demonstrate that a cangrelor IV infusion would maintain levels of platelet reactivity <240 P2Y12 Reaction Units (PRU) throughout the pre-operative period as measured by a P2Y12 assay. Platelet inhibition results are shown in this press release:


'/>"/>

Contact: Rebecca Hollins
rebecca.hollins@themedco.com
973-290-6081
The Medicines Company
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Scripps research team solves structure of beneficial virus
2. Scripps research team sheds light on immune system suppression
3. Scripps Florida scientists awarded $1.5M to fight major water and food parasites
4. Scripps research scientists identify compounds for stem-cell production from adult cells
5. Scripps research scientists identify blood component that turns bacteria virulent
6. Scripps research team defines new painkilling chemical pathway
7. Dolphin population stunted by fishing activities, Scripps/NOAA study finds
8. Scripps Research scientists shed light on how DNA is unwound so that its code can be read
9. Scripps scientists develop first examples of RNA that replicates itself indefinitely
10. Scripps scientists create first crystal structure of an intermediate particle in virus assembly
11. Historical photographs expose decline in Floridas reef fish, new Scripps study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scripps Health/the Medicines Company announce late breaking BRIDGE trial results presented at TCT
(Date:12/22/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ... "The Global Watermarking and Fingerprinting Markets" report ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides an ... fingerprinting markets. Watermarking aims to control and monitor ...
(Date:12/19/2014)... ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) has announced the addition of ... Market" report to their offering. ... market is estimated to grow at a CAGR of 3.6% ... larger share in this market, Canada ...
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) has ... - Home Button Synaptics Fingerprint Sensor Technology Analysis" ... http://photos.prnewswire.com/prnh/20130307/600769 Based on a totally different ... the first time a fingerprint sensor in its product. ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... WALTHAM, MA April 1, 2011 Avila ... drugs, today announced the publication of a scientific ... titled "The Resurgence of Covalent Drugs" ( www.nature.com/reviews/drugdisc , ... discusses the broad opportunities for covalent drugs and how ...
... never good for you, but washing that meal down with ... of Guelph study. Researcher Marie-Soleil Beaudoin has discovered not ... eating a high-fat meal, but that the spike doubles after ... to levels similar to those of people at risk for ...
... muscle strength. Not only can adults fight the battle ... Golden Years can be a time to get stronger, say experts ... exercise is a great way to increase lean muscle tissue and ... life," says Mark Peterson, Ph.D., a research fellow in the U-M ...
Cached Biology News:New opportunities for covalent drugs published by Avila scientists 2Got a craving for fast food? Skip the coffee, study says 2Older and stronger: Progressive resistance training can build muscle, increase strength as we age 2Older and stronger: Progressive resistance training can build muscle, increase strength as we age 3Older and stronger: Progressive resistance training can build muscle, increase strength as we age 4
(Date:1/22/2015)... , Nueva Jersey , 22 de enero de ... Biomedical Research abre hoy su llamada a nominaciones para ... investigación científica ha hecho, o tiene el potencial para ... humana. Las nominaciones se aceptarán hasta el 15 de ...
(Date:1/22/2015)... N.J. , Jan. 22, 2015  Derma Sciences, ... regeneration company focused on advanced wound care, announces ... placental tissues, have been added to the Premier, ... increases the opportunity for the AMNIOEXCEL® and AMNIOMATRIX® ...
(Date:12/24/2014)... 24, 2014  Vermillion, Inc. (Nasdaq:   VRML), a ... today that the Company closed its previously announced ... Jack W. Schuler , Birchview Fund LLC ... million, before offering expenses.  The proceeds will be ...
(Date:12/24/2014)... 23, 2014 Earlier this year in a ... of the Adult Stem Cell Technology Center, LLC ( ASCTC ... unique property of adult tissue stem cells. His title ... Important for the Future,” embodied the essence of his message ...
Breaking Biology Technology:El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
... 6 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" ... Phase II study of intravenous REOLYSIN(R) in patients with ... at the 15th Annual Connective Tissue Oncology Society Meeting ... 7th. The poster presentation, entitled "A Phase II Study ...
... . Fuel economy ratings for the new ... www.fueleconomy.gov web site, which Oak Ridge National Laboratory developed ... U.S. Environmental Protection Agency. Nine of the top 10 vehicles ... by the Toyota Prius (51 MPG city; 48 highway). "This ...
... , PARSIPPANY, N.J., Nov. 5 DSM Pharmaceutical Products ... with Galenix, Saint Jean D,Illac, France, where DSM will ... commercial products on a global basis. , DSM and ... drug delivery technologies, based on the strength of Galenix ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 2November 2009 story tips from the US Department of Energy's Oak Ridge National Laboratory 3DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
... fluorescent and highly photostable FluoSpheres microspheres ... a variety of applications requiring probes ... Unfortunately, protein- and other macromolecule-labeled microspheres ... them to bind to non-target surfaces ...
SMVT (N-14)...
... H2OBIT™ is a fully licensed, high throughput, water ... of up to 24 microplates. This equates to ... A robotic arm rapidly transfers a ... in temperature ramping times that are considerably faster ...
Biology Products: